Celyad
we care · we cure

Press Release
5 October 2015
07:00 am CET

Celyad CEO Invited to Present at 2015 Stem Cell Meeting on the Mesa

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that Dr Christian Homsy, Chief Executive Officer, will present and participate in a panel discussion at the upcoming Stem Cell Meeting on the Mesa being held October 7-9, 2015 in La Jolla, CA, USA.

Dr. Homsy will present during the Partnering Forum event on Wednesday, October 7, 2015 at 11:15 a.m. Pacific Time. He will discuss Celyad's recent developments, including the Company's lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure. Additionally, Dr. Homsy will join executives from Cell Therapy Catapult and uniQure NV on a panel entitled "State of the Cell & Gene Therapy Sector in Europe" on Thursday, October 8, 2015 at 9:45 a.m. Pacific Time.

Dr. Christian Homsy, CEO of Celyad, commented, "I am honored to present the Celyad story and participate in this panel at Meeting on the Mesa, one of the preeminent conferences in our industry. I look forward to sharing the details of our ongoing C-Cure and CAR-T cell development programs during our presentation and to sharing the stage with fellow leaders in the European cell therapy field to discuss some of the unique opportunities our companies and industry face."

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the Stem Cell Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the regenerative medicine and advanced therapies industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first and only event of its kind dedicated solely to facilitating connections in this sector. Combined, these meetings attract nearly 800 attendees, fostering key partnerships through more than 500 one-on-one meetings while highlighting the significant clinical and commercial progress in the field over the past year.

END

Press Release
5 October 2015
07:00 am CET

For more information, please contact:

For Europe : Consilium Strategic Communications
Amber Fennell, **Chris Gardner**, **Chris Welsh**, and **Laura Thornton -** T: +44 (0)20 3709 5700 – celyad@consilium-comms.com

For the U.S. : The Ruth Group
Lee Roth (Investors), and **Kirsten Thomas** (Media) - T: +1 646 536 7012 / 7014 - celyad@theruthgroup.com

For France : NewCap
Pierre Laurent and **Nicolas Mérigeau -** T: + 33(0)1 44 71 94 94 - celyad@newcap.fr

Celyad
Christian Homsy, CEO and **Patrick Jeanmart**, Chief Financial Officer : T: +32 (0)10 39 41 00 - investors@celyad.com

To subscribe to Celyad's newsletter, visit www.celyad.com
Follow us on Twitter @CelyadSA and on LinkedIn

About Celyad

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrollment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015.

Celyad's ordinary shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD and Celyad's American Depositary Shares are listed on the NASDAQ Global Market under the ticker symbol CYAD.

To learn more about Celyad, please visit www.celyad.com

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, including statements about the safety and efficacy of Celyad's product candidates, the potential clinical and commercial potential of these product candidates and the adequacy of Celyad's financial resources, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including risks associated with conducting clinical trials; the risk that DSMB's determination not to discontinue the Phase III clinical trials for C-Cure® on the basis of non-futility is not a determination as to the likelihood of success and is not a guarantee that the trial will be successful; the risk that safety, bioactivity and efficacy demonstrated in earlier clinical or pre-clinical studies may not be replicated in subsequent studies; risk associated with the timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKG2D CAR T-cell; risks associated with the satisfaction of regulatory and other requirements; risks associated with the actions of regulatory bodies and other governmental authorities; risks associated with obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; risks associated with competition from others developing products for similar uses; risks associated with our ability to manage operating expenses;, and risks associated with our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. A further list and description of these risks, uncertainties and other risks can be found in the Company's Securities and Exchange Commission filings and reports, including in the Company's prospectus filed with the SEC on June 19, 2015 and future filings and reports by the Company. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.